PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.29
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.14. Howard Marks would check for debt covenant compliance and refinancing risks.
-2.01
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 0.71. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-3.60
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
5.64
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.62. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
43.49%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.52%. Michael Burry would check for aggressive accounting and hidden risks.